{"id":30518,"date":"2024-12-03T15:11:32","date_gmt":"2024-12-03T09:41:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30518"},"modified":"2024-12-03T15:11:34","modified_gmt":"2024-12-03T09:41:34","slug":"pharma-news-for-applied-therapeutics-alnylam-rigel","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel","title":{"rendered":"FDA Grants Fast Track for Lin BioScience\u2019s LBS-007; Alnylam\u2019s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS."},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ecda0e00aab\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ecda0e00aab\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\/#Lin_BioScience_Receives_FDA_Fast_Track_Designation_for_LBS-007\" >Lin BioScience Receives FDA Fast Track Designation for LBS-007<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\/#FDA_Reviews_Alnylams_sNDA_for_Expanded_AMVUTTRA_Use\" >FDA Reviews Alnylam&#8217;s sNDA for Expanded AMVUTTRA Use<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\/#FDA_Approves_AOP_Healths_RAPIBLYK_Landiolol_for_Atrial_Fibrillation_and_Flutter_in_Critical_Care\" >FDA Approves AOP Health\u2019s RAPIBLYK (Landiolol) for Atrial Fibrillation and Flutter in Critical Care<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\/#Applied_Therapeutics_Receives_Complete_Response_Letter_from_FDA_for_Govorestat_NDA_for_Classic_Galactosemia\" >Applied Therapeutics Receives Complete Response Letter from FDA for Govorestat NDA for Classic Galactosemia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\/#Rigel_Announces_FDA_Fast_Track_Designation_for_R289_in_Lower-Risk_MDS\" >Rigel Announces FDA Fast Track Designation for R289 in Lower-Risk MDS<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-lin-bioscience-receives-fda-fast-track-designation-for-lbs-007\"><span class=\"ez-toc-section\" id=\"Lin_BioScience_Receives_FDA_Fast_Track_Designation_for_LBS-007\"><\/span>Lin BioScience Receives FDA Fast Track Designation for LBS-007<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Lin BioScience, a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute leukemia, announced that its lead pipeline candidate, LBS-007, has been granted Fast Track Designation by the FDA for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\" class=\"ek-link\">treatment of acute myeloid leukemia<\/a>. The company is currently conducting a Phase I\/II trial of LBS-007 in patients with relapsed or resistant acute leukemias across the U.S., Australia, and Taiwan. In addition to Fast Track Designation, Lin BioScience has also received Orphan Drug Designation (ODD) from the FDA for both AML and <a href=\"https:\/\/chatgpt.com\/c\/674d3881-a4e0-800d-9782-8dbff0e17603\" class=\"ek-link\">acute lymphocytic leukemia<\/a>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Tom Lin, Chairman of Lin BioScience, expressed enthusiasm about the designation, saying, &#8220;We are thrilled to see LBS-007 showing signs of early treatment response and potential efficacy in addressing this critical unmet medical need. Receiving FDA Fast Track Designation is a significant milestone, offering an expedited pathway to advance the development of this promising therapy. We remain deeply committed to delivering transformative solutions for patients in need.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Irene Wang, President and Chief Scientific Officer of Lin BioScience, highlighted the positive safety profile of LBS-007, stating, &#8220;During the Phase I dose escalation, we have not observed any Definitely or Probably Related Adverse Effects in all patients who have received low to high doses, demonstrating the safety profile is very tolerable and promising.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-reviews-alnylam-s-snda-for-expanded-amvuttra-use\"><span class=\"ez-toc-section\" id=\"FDA_Reviews_Alnylams_sNDA_for_Expanded_AMVUTTRA_Use\"><\/span>FDA Reviews Alnylam&#8217;s sNDA for Expanded AMVUTTRA Use<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Alnylam Pharmaceuticals has announced that the FDA has accepted its supplemental new drug application (sNDA) for AMVUTTRA (vutrisiran) to expand its label for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/transthyretin-amyloidosis-market\" class=\"ek-link\">treatment of transthyretin amyloidosis with cardiomyopathy<\/a>. AMVUTTRA, an RNA interference (RNAi) therapeutic, is currently approved for treating adult patients with polyneuropathy associated with <a href=\"https:\/\/www.delveinsight.com\/report-store\/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market\" class=\"ek-link\">hereditary transthyretin-mediated (hATTR) amyloidosis<\/a> in the U.S. and in the EU for hATTR amyloidosis in adults with stage 1 or 2 polyneuropathy.<\/p>\n\n\n\n<p>The FDA has accepted the sNDA for review under the Priority Review pathway, which shortens the review period to four months. A final decision on the application is expected by March 23, 2025. Notably, the FDA has indicated that it will not convene an advisory committee meeting for this application, streamlining the approval process. If approved, AMVUTTRA will become the first therapy in the U.S. to treat both the polyneuropathy and cardiomyopathy manifestations of ATTR amyloidosis.<\/p>\n\n\n\n<p>The application for expanding AMVUTTRA\u2019s indication is supported by the positive results from Alnylam&#8217;s pivotal Phase III HELIOS-B study, which met all primary and secondary endpoints, demonstrating statistical significance in both the overall and monotherapy populations. These promising results have further bolstered the potential of vutrisiran in treating ATTR-CM.<\/p>\n\n\n\n<p>Alnylam\u2019s progress has also been reflected in its stock performance, with shares gaining 31.1% year-to-date, outperforming the broader industry, which has seen a 9% decline. This milestone marks a significant step forward in the company&#8217;s commitment to providing innovative treatments for rare and serious diseases like ATTR amyloidosis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-aop-health-s-rapiblyk-landiolol-for-atrial-fibrillation-and-flutter-in-critical-care\"><span class=\"ez-toc-section\" id=\"FDA_Approves_AOP_Healths_RAPIBLYK_Landiolol_for_Atrial_Fibrillation_and_Flutter_in_Critical_Care\"><\/span>FDA Approves AOP Health\u2019s RAPIBLYK (Landiolol) for Atrial Fibrillation and Flutter in Critical Care<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AOP Health, based in Vienna, Austria, announced that the FDA had granted approval for RAPIBLYK (landiolol) in the critical care setting for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/supraventricular-tachycardia-market\" class=\"ek-link\">treatment of supraventricular tachycardia<\/a>, specifically <a href=\"https:\/\/www.delveinsight.com\/report-store\/atrial-fibrillation-market\" class=\"ek-link\">atrial fibrillation<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/atrial-flutter-market\" class=\"ek-link\">atrial flutter<\/a>. This approval provides U.S. patients with a new therapeutic option for rapidly managing heart rate in intensive care units. RAPIBLYK (landiolol) has shown significant promise in clinical studies, demonstrating effective heart rate management with minimal impact on blood pressure.<\/p>\n\n\n\n<p>The approval is based on data from five randomized, double-blind, placebo-controlled clinical trials, involving 317 adults with supraventricular tachycardia. The studies revealed that RAPIBLYK (landiolol) was effective in reducing the heart rate by 40-90% within about 10 minutes, compared to 0-11% in the placebo group. Heart rate reduction was defined as a more than 20% decrease in heart rate, a heart rate of less than 100 bpm, or at least intermittent cessation of the arrhythmia. While some adverse events were reported in the landiolol group (9.9%), these were much fewer than in the placebo group (1%).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>This approval marks an important milestone for AOP Health, as it expands its critical care offerings to the U.S. market. Dr. Martin Steinhart, CEO of AOP Health, expressed the significance of the approval, stating, &#8220;RAPIBLYK approval in the U.S. represents an important milestone for patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter, who need rapid and short-term heart rate reduction.&#8221; He added, \u201cWe are delighted that this therapeutic option, already available in Europe, can now help U.S. patients as well.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>AOP Health continues to focus on providing solutions for rare diseases and critical care, and this approval strengthens the company&#8217;s mission to make a meaningful impact on patient outcomes, particularly in the treatment of severe heart conditions like atrial fibrillation and atrial flutter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-applied-therapeutics-receives-complete-response-letter-from-fda-for-govorestat-nda-for-classic-galactosemia\"><span class=\"ez-toc-section\" id=\"Applied_Therapeutics_Receives_Complete_Response_Letter_from_FDA_for_Govorestat_NDA_for_Classic_Galactosemia\"><\/span>Applied Therapeutics Receives Complete Response Letter from FDA for Govorestat NDA for Classic Galactosemia<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Applied Therapeutics, Inc. announced that the FDA has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for govorestat. Govorestat is a novel, CNS-penetrant aldose reductase inhibitor (ARI) being developed for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/galactosemia-market\" class=\"ek-link\">treatment of Classic Galactosemia<\/a>. The FDA\u2019s decision was based on deficiencies identified in the clinical application, meaning the NDA cannot be approved in its current form.<\/p>\n\n\n\n<p>The company is reviewing the FDA\u2019s feedback and plans to request a meeting with the agency to discuss the next steps, including potential resubmission of the NDA or an appeal. Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics, expressed disappointment in the decision, stating, \u201cOur strong commitment to the Galactosemia community is rooted in our belief that govorestat has the potential to change the lives of patients with Galactosemia, as evidenced by the breadth of efficacy and safety data.\u201d<\/p>\n\n\n\n<p>Despite the setback, govorestat has shown promising results in clinical trials, demonstrating rapid and sustained reductions in galactitol levels, along with clinical benefits in children with Galactosemia aged 2-17. In the Phase III ACTION-Galactosemia Kids study, govorestat improved daily activities, cognition, behavior, and fine motor skills, while also reducing tremors. Additionally, govorestat has displayed a favorable safety profile, further supporting its potential as a therapeutic option for this underserved patient population.<\/p>\n\n\n\n<p>Beyond Classic Galactosemia, govorestat is also being developed for Sorbitol Dehydrogenase (SORD) Deficiency, a rare neuromuscular disease. The company anticipates submitting an NDA for SORD in early 2025. Importantly, the development of govorestat for SORD is independent of the ongoing review for Classic Galactosemia. Applied Therapeutics remains dedicated to addressing the high unmet medical need for patients with these rare conditions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-rigel-announces-fda-fast-track-designation-for-r289-in-lower-risk-mds\"><span class=\"ez-toc-section\" id=\"Rigel_Announces_FDA_Fast_Track_Designation_for_R289_in_Lower-Risk_MDS\"><\/span>Rigel Announces FDA Fast Track Designation for R289 in Lower-Risk MDS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Rigel Pharmaceuticals, Inc. announced that the FDA has granted Fast Track designation to R289 for the treatment of patients with previously treated, transfusion-dependent <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelodysplastic-syndrome-market\" class=\"ek-link\">lower-risk myelodysplastic syndrome (LR-MDS)<\/a>. R289, a potent and selective dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in an ongoing Phase Ib study. The study is focused on assessing the safety, tolerability, pharmacokinetics, and preliminary activity of R289 in LR-MDS patients who have relapsed or are refractory to prior treatments.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Raul Rodriguez, Rigel\u2019s president and CEO, expressed his enthusiasm for the Fast Track designation, stating, \u201cWe are pleased that R289 has been granted Fast Track designation, which underscores the significant unmet need for patients with transfusion-dependent lower-risk MDS. By targeting inflammatory signaling, we believe that R289 has the potential to meaningfully improve the lives of those living with this disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Lisa Rojkjaer, Rigel\u2019s chief medical officer, highlighted the importance of the designation for the primarily elderly LR-MDS patient population, who face progressive cytopenias, particularly anemia. \u201cThis designation is based on initial data from the ongoing Phase 1b study and highlights the potential of R289 to be a new therapeutic option for these patients,\u201d she said. \u201cWe look forward to working closely with the FDA to advance the clinical development of R289.\u201d<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Lin BioScience Receives FDA Fast Track Designation for LBS-007 Lin BioScience, a clinical-stage biopharmaceutical company focused on developing innovative therapies for acute leukemia, announced that its lead pipeline candidate, LBS-007, has been granted Fast Track Designation by the FDA for the treatment of acute myeloid leukemia. The company is currently conducting a Phase I\/II trial [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[12078,18089,97,204,704,349,21278,420,639,5789,1939],"industry":[17225],"therapeutic_areas":[17242,17240,17238,17233,17228],"class_list":["post-30518","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-acute-lymphocytic-leukemia","tag-acute-myeloid-leukemia","tag-atrial-fibrillation","tag-delveinsight","tag-fda","tag-latest-pharma-news","tag-myelodysplastic-syndrome-market","tag-news","tag-pharma-news","tag-recent-pharma-news","tag-transthyretin-amyloidosis","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Alnylam, Applied, Rigel<\/title>\n<meta name=\"description\" content=\"Lin BioScience\u2019s LBS-007, Alnylam Pharmaceuticals\u2019 AMVUTTRA, AOP Health\u2019s RAPIBLYK, Applied Therapeutics\u2019 Govorestat, Rigel&#039;s R289\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Alnylam, Applied, Rigel\" \/>\n<meta property=\"og:description\" content=\"Lin BioScience\u2019s LBS-007, Alnylam Pharmaceuticals\u2019 AMVUTTRA, AOP Health\u2019s RAPIBLYK, Applied Therapeutics\u2019 Govorestat, Rigel&#039;s R289\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T09:41:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T09:41:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/03150226\/pharma-news-for-applied-therapeutics-alnylam-rigel.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Alnylam, Applied, Rigel","description":"Lin BioScience\u2019s LBS-007, Alnylam Pharmaceuticals\u2019 AMVUTTRA, AOP Health\u2019s RAPIBLYK, Applied Therapeutics\u2019 Govorestat, Rigel's R289","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Alnylam, Applied, Rigel","og_description":"Lin BioScience\u2019s LBS-007, Alnylam Pharmaceuticals\u2019 AMVUTTRA, AOP Health\u2019s RAPIBLYK, Applied Therapeutics\u2019 Govorestat, Rigel's R289","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-03T09:41:32+00:00","article_modified_time":"2024-12-03T09:41:34+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/03150226\/pharma-news-for-applied-therapeutics-alnylam-rigel.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel","name":"Pharma News | Alnylam, Applied, Rigel","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2024-12-03T09:41:32+00:00","dateModified":"2024-12-03T09:41:34+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Lin BioScience\u2019s LBS-007, Alnylam Pharmaceuticals\u2019 AMVUTTRA, AOP Health\u2019s RAPIBLYK, Applied Therapeutics\u2019 Govorestat, Rigel's R289","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-applied-therapeutics-alnylam-rigel"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute lymphocytic leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Myeloid Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atrial Fibrillation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">transthyretin amyloidosis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute lymphocytic leukemia<\/span>","<span class=\"advgb-post-tax-term\">Acute Myeloid Leukemia<\/span>","<span class=\"advgb-post-tax-term\">Atrial Fibrillation<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Myelodysplastic Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">transthyretin amyloidosis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 3, 2024","modified":"Updated on Dec 3, 2024"},"absolute_dates_time":{"created":"Posted on Dec 3, 2024 3:11 pm","modified":"Updated on Dec 3, 2024 3:11 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30518"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30518\/revisions"}],"predecessor-version":[{"id":30523,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30518\/revisions\/30523"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30518"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30518"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}